Skip to main content

Table 5 Non-susceptibility rates of the most prevalent non-invasive bacterial pathogens from Gabon

From: Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa

Pathogen (n) Antimicrobial non-susceptibility (%)
PEN/AMPa COX AMP + BLI CRO GEN CIP CHL CLI ERY SXT TCY
S. aureus (312) 94.2 8.33 8.33 8.33 2.3 9.4 0.9 2.5 17.0 8.3 37.5
S. pyogenes (69) 8.6 - - 0 - - 9.1 7.8 7.9 56.0 -
S. pneumoniae (19) 6.7 - - ND - - 14.3 10.5 11.1 82.4 ND
E. faecalis (19) 0 - - - - 81.3 - - - - -
K. pneumoniae (56) 100 - 51.9 38.9 38.2 21.4 55.6 - - 60 ND
P. agglomerans (6) 83.3 - 75.5 ND 0 0 ND - - 0 ND
P. aeruginosa (39) - - 0b 0c 0d 2.6 - - - - -
P. mirabilis (52) 34.6 - 17.3 2.1 13.5 1.9 44.4 - - 48.9 ND
E. coli (114) 80.4 - 60.3 16.4 14.7 24.1 35.5 - - 88.1 ND
S. enterica (9) 22.2 - ND 0 0 0 0 - - 12.5 0
  1. Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates are shown as the percentage of tested isolates.
  2. aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives and E. faecalis to ampicillin.
  3. bNon-susceptibility to piperacillin/tazobactam.
  4. cNon-susceptibility to ceftazidim.
  5. dNon-susceptibility to amikacin.